Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Silverdale, WA
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Silverdale, WA
Click here to add this to my saved trials
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated:  11/28/2017
Clinical Research Facility
mi
from
Madison, WI
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Enrolling
Updated: 11/28/2017
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Water Drinking Test in Patients With Occludable Angle
What is the Effect of the "Water Drinking Test" on Patients With Narrow Angles on the Day of Their Scheduled Laser Iridotomy?
Status: Enrolling
Updated:  11/28/2017
Wills Eye Institute
mi
from
Philadelphia, PA
Water Drinking Test in Patients With Occludable Angle
What is the Effect of the "Water Drinking Test" on Patients With Narrow Angles on the Day of Their Scheduled Laser Iridotomy?
Status: Enrolling
Updated: 11/28/2017
Wills Eye Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Electronic Applications for Patients With Glaucoma
A Smartphone- and Tablet-Based Application for Patients With Glaucoma
Status: Enrolling
Updated:  11/28/2017
Wills Eye Hospital
mi
from
Philadelphia, PA
Electronic Applications for Patients With Glaucoma
A Smartphone- and Tablet-Based Application for Patients With Glaucoma
Status: Enrolling
Updated: 11/28/2017
Wills Eye Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
Status: Enrolling
Updated:  11/29/2017
Penn State Hershey Eye Center
mi
from
Hershey, PA
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
Status: Enrolling
Updated: 11/29/2017
Penn State Hershey Eye Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Suture Contamination Rate in Adjustable Suture Strabismus Surgery
Suture Contamination Rate in Adjustable Suture Strabismus Surgery
Status: Enrolling
Updated:  11/29/2017
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
Suture Contamination Rate in Adjustable Suture Strabismus Surgery
Suture Contamination Rate in Adjustable Suture Strabismus Surgery
Status: Enrolling
Updated: 11/29/2017
Bascom Palmer Eye Institute, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
Dexamethasone Intravitreal Implant for Retinal Vein Occlusion Associated Macular Edema After Treatment Failure With Anti-VEGF Medications
Status: Enrolling
Updated:  11/29/2017
The Retina Institute
mi
from
Saint Louis, MO
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
Dexamethasone Intravitreal Implant for Retinal Vein Occlusion Associated Macular Edema After Treatment Failure With Anti-VEGF Medications
Status: Enrolling
Updated: 11/29/2017
The Retina Institute
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2
Status: Enrolling
Updated:  12/1/2017
Univ of Massachusetts Med School
mi
from
Worcester, MA
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2
Status: Enrolling
Updated: 12/1/2017
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2
Status: Enrolling
Updated:  12/1/2017
Casey Eye Institue, Oregon Health & Science University
mi
from
Portland, OR
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2
Status: Enrolling
Updated: 12/1/2017
Casey Eye Institue, Oregon Health & Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
An Open Label, Pilot (Phase I/II), Dose-Escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration.
Status: Enrolling
Updated:  12/4/2017
Wilmer Eye Institute
mi
from
Baltimore, MD
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
An Open Label, Pilot (Phase I/II), Dose-Escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration.
Status: Enrolling
Updated: 12/4/2017
Wilmer Eye Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Austin, TX
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Peoria, AZ
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Peoria, AZ
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Tucson, AZ
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Irvine, CA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Irvine, CA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Loma Linda, CA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Poway, CA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Poway, CA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Santa Ana, CA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Golden, CO
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Golden, CO
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Fort Myers, FL
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Winter Haven, FL
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Chicago, IL
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Leawood, KA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Leawood, KA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Paducah, KY
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Paducah, KY
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Baltimore, MD
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Boston, MA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Royal Oak, MI
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Traverse City, MI
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Traverse City, MI
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
New York, NY
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Asheville, NC
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Charlotte, NC
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Beachwood, OH
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Beachwood, OH
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Cleveland, OH
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Columbus, OH
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Ashland, OR
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Ashland, OR
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Portland, OR
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Dallas, TX
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Seattle, WA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Silverdale, WA
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Silverdale, WA
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Madison, WI
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/7/2017
GSK Investigational Site
mi
from
Sydney,
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/7/2017
GSK Investigational Site
mi
from
Sydney,
Click here to add this to my saved trials
Macular Degeneration and Aging Study
Improving Care Planning and Well-being in Older Adults With Macular Degeneration
Status: Enrolling
Updated:  12/11/2017
University of Rochester
mi
from
Rochester, NY
Macular Degeneration and Aging Study
Improving Care Planning and Well-being in Older Adults With Macular Degeneration
Status: Enrolling
Updated: 12/11/2017
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated:  12/11/2017
Golden Optometric Group
mi
from
Whittier, CA
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated: 12/11/2017
Golden Optometric Group
mi
from
Whittier, CA
Click here to add this to my saved trials
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated:  12/11/2017
Coan Eye Care & Optical Boutique
mi
from
Ocoee, FL
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated: 12/11/2017
Coan Eye Care & Optical Boutique
mi
from
Ocoee, FL
Click here to add this to my saved trials
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated:  12/11/2017
Cornea & Contact Lens Institute of Minnesota
mi
from
Edina, MN
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated: 12/11/2017
Cornea & Contact Lens Institute of Minnesota
mi
from
Edina, MN
Click here to add this to my saved trials
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated:  12/11/2017
Sacco Eye Group
mi
from
Vestal, NY
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
Status: Enrolling
Updated: 12/11/2017
Sacco Eye Group
mi
from
Vestal, NY
Click here to add this to my saved trials